When do biologic drug patents expire and when will biosimilars launch?

United States Patent 5,846,534 Landscape: Scope of Campath-1–Binding Human Antibodies, Formulation Claims, and Expiration/Validity Exposure

US Patent 5,846,534 covers human-origin (framework and constant) antibodies that bind the antigen Campath-1, with tightly specified heavy/light variable region CDR definitions and specific framework residues (notably heavy-chain framework residue 27 = phenylalanine). It also extends to antibody compositions (diluent, purity limit, IV use, unit dose 1–20 mg including 5 mg) and methods for treating human lymphoid malignancies (including lymphoma) by administering the claimed antibody, including IV dosing and combination with another therapeutic antibody.

Because the claims recite specific amino-acid positions within CDRs/frameworks and prescribe a particular IV dosage range/unit dose and purity threshold, the enforceable “center of gravity” is narrow: antibodies that are sequence-close and match the positional constraints, plus dosage/formulation variants within the claimed parameters. The broader therapeutic concept (treating lymphoid malignancy with anti-Campath-1 antibodies) is partially constrained by the requirement that the administered antibody match the specific sequence/region architecture in claims 1–6.

What claims are actually in US 5,846,534 for anti–Campath-1 antibodies?

Answer: The patent has three claim clusters: (i) a structural antibody claim tied to exact CDR/framework residue positions and human-origin regions, (ii) composition claims focused on IV-administration and purity/unit dose, and (iii) method claims for lymphoid malignancies (with lymphoma subset), including IV delivery and combination regimens.

Claim 1: Core antibody definition is sequence-and-position constrained

Claim 1 requires an antibody that:

Binds effectively to “the antigen Campath-1.”
Has human-origin constant regions.
Has heavy and light chain variable domain framework regions of human origin.
Has CDRs defined by specific amino-acid residue ranges:
- Heavy-chain CDR amino acids: 31–35, 50–65, 95–102 (as in FIG. 2a)
- Light-chain CDR amino acids: 24–34, 50–56, 89–97 (as in FIG. 2b)
Includes a specific framework residue constraint: heavy-chain framework residue 27 = phenylalanine.

This is not a generic anti-Campath-1 antibody claim. It is a “sequence-anchored” claim: even if an antibody binds Campath-1, it does not fall within the literal claim unless it also meets the prescribed human-origin framework/constant structure and matches the positional CDR definitions and the F27 constraint.

Claim 2: Heavy-chain framework residue 30 is threonine

Claim 2 narrows claim 1 by requiring:

Heavy-chain framework residue 30 = threonine.

Claims 3 and 4: Full variable domain residue coverage defined by FIG. 2a/2b ranges

Claim 3 defines:

Light chain variable domain residues: 1–108 (FIG. 2b upper sequence)
Heavy chain variable domain residues: 1–26, 28–113 (FIG. 2a upper sequence)
with residue 27 = phenylalanine.

Claim 4 further narrows claim 3 by requiring:

Heavy chain includes residues 1–26, 28, 29, and 31–113 (still leaving residue positions consistent with the figure’s sequence architecture), with:
- residue 27 = phenylalanine
- residue 30 = threonine

These dependent claims expand precision rather than breadth: they attempt to lock in the variable domain content to what is shown in the patent figures and the specified residue omissions/placements.

Claims 5 and 6: Constant-region subclass constraints (IgG and IgG1)

Claim 5: heavy-chain constant domains are IgG class.
Claim 6: heavy-chain constant domains are IgG1.

That limits potential literal coverage to IgG1 constant structures (if Claim 6 is asserted, IgG1 is required).

Claims 7–12: Composition claims include purity limit and dosing

Claim 7:

“A composition for administration” comprising the claimed antibody plus a physiologically acceptable diluent or carrier.

Claim 8:

purity: “no more than 5% by weight of other biological materials.”

This is an enforceability lever. Many manufacturing processes yield products with trace host-cell proteins, aggregates, or other biologics. The claim attempts to define a composition purity threshold that could be used to distinguish formulations.

Claim 9:

adapted for intravenous administration.

Claim 10:

additionally comprises another therapeutic antibody (combination product concept).

Claim 11:

unit dosage: 1 to 20 mg of antibody.

Claim 12:

unit dosage is 5 mg.

These claims tie dosing and IV formulation to the claimed antibody identity. A competitor’s product that matches sequence but differs in unit dose or fails the purity threshold is potentially outside literal scope, depending on how “unit dosage” and “purity” are measured in the asserted context.

Claims 13–18: Method-of-treatment claims track the antibody and route/dose

Claim 13:

treating human patient with lymphoid malignancy by administering the specific Campath-1-binding human antibody defined in claim 1.

Claim 14:

patient has lymphoma.

Claim 15:

administered intravenously.

Claim 16:

administered together with another therapeutic antibody.

Claim 17:

unit dosage 1 to 20 mg.

Claim 18:

unit dosage 5 mg.

The method claims are essentially “use of the specific claimed antibody” with IV and dose parameters. They are not broad to “any anti-Campath-1 antibody”; they are constrained by the underlying antibody definition.

How narrow is the claim scope based on the residue-position language?

Answer: Extremely narrow on the antibody itself, with an additional narrow layer on IgG1 constant region (if Claim 6), purity (Claim 8), route (IV), and unit dose (5 mg included in Claims 12 and 18).

Key narrowing anchors in the antibody claims

CDR residue range definitions tied to FIG. 2a/2b
The claims define CDRs by amino acid residue numbers (heavy: 31–35/50–65/95–102; light: 24–34/50–56/89–97). That makes literal infringement depend on alignment to the numbered sequences in the patent figure.
Heavy-chain framework residue 27 = phenylalanine
This is a single-residue constraint that can be decisive if alternate antibodies substitute at that position.
Heavy-chain framework residue 30 = threonine (Claims 2 and 4)
This adds another positional constraint.
Framework and constant regions “of human origin”
This can matter for chimeric constructs. But because the claims also specify framework residue types and the variable domain sequence content by range (Claims 3/4), “human origin” is reinforced by the positional/sequence limitations.
IgG1 constant region (Claim 6)
If a competitor uses an IgG2/IgG4 constant, they may avoid Claim 6 (and possibly Claim 5 if not IgG class).

How the formulation and dosing claims further limit coverage

Purity cap: ≤5% other biological materials.
IV route: Claim 9 and method Claim 15.
Unit dose: 1–20 mg; also exact 5 mg in Claims 12 and 18.

This means a competitor’s infringement analysis becomes multi-dimensional: sequence, constant class, manufacturing purity profile, and product presentation/dose.

What patents likely matter alongside US 5,846,534 for Campath-1 antibody families?

Answer: The relevant estate typically clusters into (i) foundational anti-Campath-1 antibody sequence claims, (ii) improved variants (framework/C DR substitutions and constant region formats), (iii) humanization platforms and non-obviousness improvements, (iv) formulation/dosing and IV delivery, and (v) method-of-use claims for lymphoma/lymphoid malignancies.

This question requires the actual bibliographic and citation record for US 5,846,534 (other patents cited by the examiner, patents sharing similar priority, and any terminal disclaimer status). Without those records, a definitive cross-patent map cannot be produced from the claim text alone.

When does US 5,846,534 lose exclusivity or patent term protection?

Answer: The patent’s expiration depends on its filing and priority dates, any patent term adjustment/extension, and whether terminal disclaimer(s) apply. The claim text alone does not provide those dates.

What controls U.S. patent expiration in practice

Filing date (or earliest effective priority date) drives the statutory term.
PTA/PTD can shift expiration.
Terminal disclaimers align the expiration to an earlier family member.
Any regulatory exclusivity (for biologics) is separate from patent term and does not replace patent expiry.

What Orange Book status exists for this patent?

Answer: US 5,846,534 is an antibody patent with method/formulation claims. Orange Book listings apply to approved small molecules and certain approved drug products. Biologic products are listed in the Biologics License Application (BLA) context; the relevant listing mechanism for patents tied to biologics is generally in the context of the BLA patent listing system, not the Orange Book.

The exact “Orange Book status” is not determinable from the patent claims alone without the drug product identifier and the USPTO listing records.

What generic or biosimilar entry risks exist for antibodies that target Campath-1?

Answer: Risk is driven by whether a biosimilar candidate can replicate:

the binding specificity to Campath-1,
the literal sequence constraints (CDR positional definitions and F27, plus T30 if asserted),
the IgG1 constant region (if Claim 6 is asserted),
and the product presentation: IV formulation and 1–20 mg unit dose, including 5 mg.

A practical infringement pressure point: sequence proximity

Competitors often design around specific residues or CDR patterns. Claims that enumerate residue numbers and require specific framework substitutions (F27, T30) are designed to give a designer clear “avoidance coordinates.” If an alternative antibody differs at those positions while preserving binding, the literal claims may not read.

Method-of-use design-around is harder

Even if a competitor avoids literal antibody identity, there can be argument around whether a non-literal equivalent satisfies claim interpretation. But for sequence-defined antibody claims, courts typically treat identity and equivalence as highly fact-intensive at the amino-acid level.

How strong are the claims from a legal-construction standpoint?

Answer: Strength is high for literal sequence-defined scope but limited for breadth. The patent’s enforceability depends on whether the asserted competitor’s antibody matches the same residue numbering context as the patent figures and satisfies IgG1 and (if relevant) purity/unit-dose parameters.

Claim construction likely to focus on residue numbering and FIG alignment

The claims reference residue numbering “as shown in FIG. 2a/2b.” Literal infringement analysis will require mapping the competitor’s antibody sequences into the same numbering scheme the patent uses.
Any alternate numbering scheme or alignment method can become a central dispute.

Purity and dose claims can narrow to product-specific evidence

Claim 8 requires a purity threshold “no more than 5% by weight of other biological materials.” That is measurable and can be tested via release specs and analytical results.
Claims 11–12 and method Claims 17–18 require unit dose ranges and an exact 5 mg option. A competitor presenting a different unit strength can potentially avoid literal coverage for those claims.

What settlement or Paragraph IV–type challenges are implicated?

Answer: For biologics/antibody products, “Paragraph IV” is generally a small-molecule Hatch-Wax term. The analogous mechanism for biologics is patent litigation tied to BLA patent listings. The timing and existence of any challenges against US 5,846,534 cannot be determined from the claim text alone.

How does US 5,846,534 compare with later Campath-aligned antibody portfolios?

Answer: US 5,846,534 is a sequence-defined human-origin antibody claim anchored to specific residue positions and CDR definitions. Later portfolios in the same antigen space often include:

improved humanization,
altered Fc regions for effector function modulation,
or different dosing/formulation platforms.

Without a competitor list and their exact sequences/constructs, a credible comparative landscape cannot be built.

Table: Claim-by-claim scope map (what must match to infringe)

Claim	Category	What must match (literal elements)	Practical design-around levers
1	Antibody	Binds Campath-1 antigen; human constant; human-origin VH/VL frameworks; CDR residues: heavy 31-35/50-65/95-102 (FIG.2a), light 24-34/50-56/89-97 (FIG.2b); VH framework residue 27 = Phe	Change VH position 27; alter CDR residue set/numbering; non-human constant region; non-human-origin framework
2	Antibody	Claim 1 plus VH framework residue 30 = Thr	Alter residue 30
3	Antibody	Claim 1 plus VL residues 1–108 (FIG.2b); VH residues 1–26 and 28–113 (FIG.2a); VH residue 27 = Phe	Sequence changes outside those ranges
4	Antibody	Claim 3 plus VH residues 1–26, 28, 29, 31–113; VH residue 27 = Phe; residue 30 = Thr	Modify residue 30 and/or residue pattern in VH
5	Antibody	Claim 1 plus heavy constant domains are IgG	Use non-IgG class
6	Antibody	Claim 1 plus heavy constant domains are IgG1	Use IgG2/IgG4 (if allowed)
7	Composition	Claim 1 antibody + physiologically acceptable diluent/carrier	Different carrier/delivery system (if outside physiologically acceptable diluent scope)
8	Composition	Claim 7 plus purity: ≤5% by weight other biological materials	Adjust formulation purity spec (release criteria)
9	Composition	Claim 7 plus adapted for IV administration	Non-IV route or presentation
10	Composition	Claim 7 plus includes another therapeutic antibody	Combination approach can still fall inside; needs specifics
11	Composition	Claim 7 plus unit dosage 1–20 mg	Different unit strength/presentation
12	Composition	Claim 11 with unit dose 5 mg	Different unit strength from 5 mg
13	Method	Treat human lymphoid malignancy via administering claim 1 antibody	Avoid claim 1 antibody identity
14	Method	Claim 13 plus patient has lymphoma	Clinical indication remains covered if lymphoma
15	Method	Claim 13 plus administer IV	Use different route
16	Method	Claim 15 plus administer with another therapeutic antibody	Combination therapy still potentially covered depending on identity
17	Method	Claim 13 plus unit dose 1–20 mg	Dose outside range or different unit strength
18	Method	Claim 17 plus unit dose 5 mg	Avoid 5 mg unit dosing

Key Takeaways

US 5,846,534 is built around a sequence-position anchored Campath-1–binding human antibody, with enforceable narrowing from CDR residue range definitions and specific VH framework residues (F27; also T30 in dependent claims).
The estate covers product presentation: IV-administration, purity cap (≤5% other biological materials), and unit dose constraints (including 5 mg).
The method claims map to treating lymphoid malignancy (including lymphoma) using the specific claimed antibody with IV and dose parameters.
Practical infringement hinges on four buckets: sequence match, constant region class (IgG1 if asserted), purity, and unit dose/route.

FAQs

Can an antibody that binds Campath-1 but differs at VH residue 27 avoid US 5,846,534 Claim 1?
Does using an IgG2 or IgG4 constant region design around the IgG1-dependent claim?
How does the ≤5% “other biological materials” purity limit affect formulation infringement analysis?
If a competitor uses a different unit strength than 5 mg, does that avoid Claims 12 and 18?
Do the method claims cover non-IV administration if the antibody identity matches Claim 1?

References

United States Patent 5,846,534, “Antibodies,” claim set as provided in the prompt.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	May 07, 2001	⤷ Start Trial	2014-04-29
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	November 14, 2014	⤷ Start Trial	2014-04-29
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	October 12, 2004	⤷ Start Trial	2014-04-29
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Country	Patent Number	Estimated Expiration
South Africa	891069	⤷ Start Trial
World Intellectual Property Organization (WIPO)	8907452	⤷ Start Trial
United States of America	6569430	⤷ Start Trial
New Zealand	227968	⤷ Start Trial
Netherlands	300067	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Patent: 5,846,534

Summary for Patent: 5,846,534